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To Randomize or Not to Randomize? 
That is the Question. 
Robert Boruch 
University of Pennsylvania 
June 15, 2018  
 
Introduction 
Women Affirming Motherhood (WAM) recently received substantial support from the 
Empire Foundation for WAM’s  work in assisting pregnant young women.   As part of the grant, 
Empire required WAM to elicit bids for an independent evaluation of  WAM’s performance.  In 
what follows, the focus is on evaluating WAM’s effects.  In particular, the concern is whether 
and how a randomized controlled trial (RCT) might be deployed so as to produce a fair estimate 
WAM’s effects. 
 The approach to addressing the concern is interrogatory, as the title suggests.  The topic’s 
handling here is more Socratic than it is Shakespearian, however.  
 
Assumptions about WAM and Interest in Its Effects 
 Program managers, foundation people, and a prospective trialist must depend on 
assumptions about the state of play.  This articled depends on Alkin and Christie’ (2017) 
characterization of the program (2017).  In particular, WAM’s targets are declared to be 
expectant mothers in low income areas.  WAM’s leadership includes able people who developed 
what they believe to be a promising program.  With foundation funding, the assumption is that 
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the WAM staff will continue to service the mothers.  If this is information is not dependable, the 
trialist may withdraw from engagement.  
The prospective trialist may assume, or must assume,  that the potential users of evidence 
about WAM’s effect are serious in this interest.  Identifying the potential users is important to 
support this assumption.  For instance, they may include WAM’s leadership and staff, the 
Empire Foundation, and other stakeholders including WAM’s target population.  For the trial’s 
design, an advisory panel that includes such people is usually helpful to the design process.   
More about this anon.    
If there is no real prospect of fair evidence being used by any of these stakeholders, or if 
there will be no serious input from stakeholders in the trial’s design, there’s not much point to a 
trialist going further.   
 
 
Interrogatory Approach to Deciding about RCTs, 
And Their Design. 
 
 In evaluation studies generally, and in deciding about whether to engage in RCTs in 
particular, three questions are fundamental.   
 Q1.  What’s the nature, severity of the problem and how do we know? 
 Q2.   Has the program that’s designed to address the problem been deployed, and how do 
we know? 
 Q3.  What’s the program’s effect and how do we know? 
 4 7/13 
 
These questions, put in other vernacular, underlie evaluation policies of some foundations, multi-
national organizations, and federal agencies in the U.S. and in textbooks on evaluation.  See for 
instance Boruch, Chao, Lee (2016) and especially the references therein. 
  Addressing the last question, about effect, depends heavily on evidential answers to the 
first two questions.  Absent good evidence on these two, designing good RCTs, or any impact 
study is likely to be unsatisfactory at best.  It may be  and futile at worst.  Each question is 
considered in the WAM context in what follows. 
 
Q1.  What’s the Nature and Magnitude of the Problem 
 and How Do We Know? 
 Alkin and Christies (2017) report that WAM’s take-up rate at the end of the first-year 
was “a little more than 100 expectant mothers were served…with demand for service increasing 
regularly…” (p2).   Page 3 of the report further avers that “…the number of young women 
seeking WAM’s services was steadily growing…” in Year 2.  This is promising for funders of 
course. 
 For a trialist however, the information is vague.  Demand is said to be “Increasing 
regularly….and steadily growing”  But the trialist must ask: by how much exactly?  “Steadily 
Ten percent?  Two percent?  What?   Determining how much is important partly because 
designing a good RCT depends on the trialist’s understanding of the number of young women in 
WAM’s pipeline.  Pipeline studies are required in advance of many RCTs in medical, 
criminological, and educational sectors.  In reporting on final results of a trial, the CONSORT 
Standards, for instance, require such information to assure transparency of RCTs results.  See 
http://www.consort-statement.org.   
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More to the point of designing a RCT so as to estimate WAM’s effects, small samples, 
such as 100-200, often require special attention from the trialist.   The mobility of the young 
women is important.   If they disappear fast from the WAM pipeline, WAM’’s effect with be 
difficult to detect or understand.  A good trialist might then suggest that WAM’s evaluation then 
be considered an exploratory effort, rather than a confirmatory or summative effort.   
In particular, the trialist may suggest that (a) the small sample study be considered as 
exploratory and (b) the  probability of outcomes be the focus  rather than formal tests of 
statistical hypotheses.    Randomization tests for instance, give a probability of a difference in 
outcomes, as opposed to inviting, or being seduced into, formal decisions about decisions based 
on a p=.05 or some other artificial threshold.  The fourth edition of the Edgington and Orghena 
(2007) book is a dependable resource on this account.   
 A rather more interesting aspect of the WAM scenario concerns WAM’s “client base,” 
referenced on page 3.  No information is provided about the base, apart from telling us that the 
young ladies are pregnant, at high risk, and living in a poor area of a mid-western city. Who 
refers the women to WAM?  More importrant, who are these young people?  Are they school 
age?  In prisons?  On welfare?  Obese?  On drugs?  Are they transient?  Or all?   Understanding 
what the client base here is important in understanding the nature and magnitude of the problem, 
and hence in designing a RCT.  Ditto for the broader context. 
 Absent dependable information on the young ladies in the WAM pipeline, it’s difficult, 
or impossible, to design a good RCT.  No decent statistical power analysis is possible, for 
instance.  No sensible interpretation of the RCT’s results, including generalizability, is possible 
absent dependable information on the WAM client base and referral system. 
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 If there is good initial evidence on these matters, the trialist may then proceed further.  
Otherwise, he or she may pull the plug, for good reason. 
 
Q2.  Is the Program Deployed and How Do We Know?  
 Over the past 40 years, big foundations have given big dollars to programs that have not 
been deployed.  Nowadays, the best foundations require evidence about this.  They ask how the 
money was spent.  Bless Empire on this account, if indeed the foundation asks WAM about the 
dollars.   
Evaluators who specialize in program implementation or formative assessments are 
typically more informative about program operations and practice than a specialist in RCTs can 
be.   Specialists in formative evaluation, for instance, can assist in understanding WAM’s 
deployment, and how WAM’s services cut across agencies.  Any given service component may 
demand attention to indicators of service delivery and receipt.  Undergirding the deployment is a 
theory of change, i.e., a set of ideas about what should happen in WAM’s service delivery and 
about what should happen to young women as a consequence of its delivery.  
 In designing a randomized trial. the prospective trialist would be foolish to ignore 
WAM’s theory of change, and the evidence that might be offered by implementation specialists 
about WAM’s deployment.  Absent such evidence, or the promise of it, the trialist may desist 
from further work. The trialist may then proceed if there is a promise of evidence on WAM’s 
deployment in addition to evidence on WAM’s client base. 
 
Q3.  What is WAM’s effect?  How Do We Know? 
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 In the case at hand, designing a randomized controlled trial depends on evidential 
answers to Questions 1, on WAMs’ pipeline and client base, and Question 2, on WAM’s 
deployment.  Let us assume that the questions have been addressed, or will be addressed as part 
of a trial.    
This get to the hard work by the trialist:  reviewing the relevant literature, identifying the 
main outcome variables, structuring the random allocation and explanations of it, sand taging a 
trial  so as to benefit from inevitable mistakes. 
Reviewing the Relevant Literature 
 Industrious trialists will inquire of colleagues who have done related work so as to learn 
from them.  For the WAM case, a trialist will try to learn from the published literature who has 
measured what in randomized field experiments  that have direct attention to young pregnant 
women in high poverty areas, how, when, and why the trial was done, and what the outcomes 
were.   
 In the health care sector, for instance, the Cochrane Collaboration regularly produces 
reviews of evidence on related programs.    The Cochrane Library covers evidence on 
effectiveness of interventions designed to avert or handle domestic violence against pregnant 
women, the antenatal issues that affect women in low income areas, and the handling of pre-natal 
and post-natal health and behavior issues among the women.  See 
http://cochranecollaboration.org.   
 
Outcome Measures 
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 Deciding which outcome variables should be measured is no easy matter in a 
multicomponent program like WAM.  WAM’s  stakeholders and Foundation people are 
important in this, as is the theory of change.  
The burden falls partly to the trialist to encourage identification of pertinent outcomes, 
and often to identify dependable ways to measure them.  The programmatic or policy  decision 
about what outcome to measure is usually not in the trialist’s purview. 
 Snares in any such negotiation on this are common.  The challenges for the trailist 
include the WAM’s opining that a dozen  outcomes are important. The health of the young 
woman and health of the baby are, to be sure, relevant.  But so too are outcomes such as the 
women’s knowledge and perhaps also her beliefs, attitudes, and observable links to the social 
networks that WAM facilitates. 
Typically, all potential outcomes are not equally important to everyone.  The trialist, must 
nonetheless seek agreement on which one or two or three outcomes have the highest priority and 
why.  Setting priorities is basic because: (a) measuring all plausible outcomes well is likely to be 
infeasible, (b) measuring lots of plausible outcomes guarantees that some effects will be positive, 
some negative, and many will be negligible, which inevitably leads to squabbles about the 
implications of results, and (c) identifying a couple of primary outcomes does not mean that 
others be ignored. The result of negotiation usually entails classifying outcome into the primary 
ones and the ones of secondary import. 
 Absent  a negotiated agreement that a couple of outcomes are high priority and can be 
measured dependably, and absent agreement that there are secondary outcomes that are 
important and measureable, a prospective trialist may excuse himself or herself without disgrace. 
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Random Allocation and Fairness 
Designing a RCT in this context requires some agreement among stakeholders about 
random allocation of pregnant young women, to WAM or to a control condition (which might be 
an existing community program).  The random allocation will yield defensible evidence that the 
estimated effect is transparent and  fair. 
 For example, if  the demand for WAM’s services far exceed WAM’s capacity to supply 
services, then random allocation of young pregnant women to the WAM program may be 
acceptable to stakeholders.  The negotiation on this may involve ethical, managerial, and 
political values.  It depends of course on the realities of the pipeline. 
 When demand exceeds supply, and when lottery allocation is acceptable to stakeholders, 
the technical issues in design are easy.  For instance, trialists have easy access to software for 
substantial power analysis, assuring that a WAM effect can be detected, e.g. Dong and Maynard 
(2013).  Trialists have easy access to technology that incorporates factors such a types of 
pregnant women (single mothers, drug users, diabetics) into the experiment’s design. 
 Statistical power analysis is merely technical.  It is not enough.  In designing the RCT, 
good trialists will review work on earlier trials on programs that seem relevant.  Systematic 
reviews, of the sort published by the Cochrane Collaboration in health and the Campbell 
Collaboration in social sectors, are relevant.  These are important to anticipate WAM’s effect 
size, to understand what outcomes are important. 
 WAM’s aims, the challenge of designing a good trial, and systematic reviews lead to a 
basic question for the trialist. What are the outcome variables?  And who says so?  And how 
might these outcomes be measured or observed dependably? 
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Ethics and Random Assignment 
 WAM’s description does not tell us that the program is mandatory, ordered by a family 
court for instance.  Assume, as is usually the case, that the women’s participation in the program 
is voluntary.  In such cases, the idea of informed consent is important.  Consent is crucial. But 
there are other ethics issues in this scenario. 
 Is the program important enough to test in a trial?  If it not, then the results of a trial may 
be trivial at best and may waste people’s time. Assume  that WAM is important enough to justify 
a trial.  Ethics questions remain. 
 If WAM’s important ingredients are known to be effective, based on earlier dependable 
evidence, deploying a randomized trial may not be warranted.  For instance, no one does Salk 
vaccine trials nowadays to test the vaccine’s effectiveness because effects have been well 
established.  One might however ethically test WAM’s variation under the assumption that it is 
potentially better than others, just as testing different doses of vaccines can be ethical. 
 Would  methods other than a randomized trial yield dependable evidence about its 
effects?   If so, randomization may not be necessary and even be unethical.  For instance, times 
series data on women in WAM’s catchment area might be sufficient,  when the interruption of 
the series, if the deployment of the program is sharp, and the time series data are adequate.  In 
the case at hand, neither “if’s” are likely to be met.   
One might explore propensity score approaches, which are more sophisticated than older 
covariance analyses.  These require identifying the right matching variables (covariates), 
measuring them in the right way, and putting them into the right functional form/model for 
reasonably defensible statistical estimates of effect. Identifying and discussing alternatives to 
random assignment as a device to produce fair comparisons are typically debatable matters.  
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Assume for the sake of argument, that the alternatives are not feasible, will not yield persuasive 
evidence, or will yield evidence that is far less transparent than a randomized trial results would 
be.  The trialist may then proceed. 
  
Explaining Random Allocation to Young Pregnant Women 
 How does one explain to pregnant young women the fact that they will  be randomly 
allocated to a special program?  Experience from other sectors suggests that explanations have to 
be tailored to the people involved.  To cut to the rhetorical chase, the word “experiment” in some 
contexts is unacceptable.  The phrase “randomized controlled trial” is meaningless in others.  
The word “lottery” may be tolerable, and familiar, in common parlance.  The idea of a lottery is 
fair in many cultures. 
 Learning how to explain well can depend on focus groups of potential WAM participants 
in anticipation of the RCT, and on the judgments of stakeholders of course.  See for instance 
Rockefeller Foundation’s video tape documentary on the Minority Female Single Parent 
Program.  The taping grew out of initially flawed efforts to explain in the trial and shows how 
explanation may differ with culture. 
  
Executing an RCT under Uncertain or Unstable  Conditions 
Absent pre-RCT efforts and evidence, the trialist will be a troubled soul.  Less troubled 
than Hamlet, but troubled nonetheless. In uncertain conditions, one option is obvious.  The 
trialist might run  the trial in two stages.  The first stage,  a “run-in trial” in engineering parlance 
is deployed  so everyone makes all the mistakes one can make.  The trialist and everyone else 
can then learn how to deploy the second stage and do  a better trial.  
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In olden days for instance, cops, nurses, and other service providers subverted the random 
allocation at times, e.g. by simply ignoring the assignment and treating the client as they pleased.  
Audits and mechanisms can be built to suit the particular setting so as to reduce or eliminate the 
problem.  Similarly, information that permits tracking of women over time can be built based on 
experience so as to reduce attrition, missing data, and so on.  Doing RCTs in stages is a no 
brainer for trialists in the social sciences, health, engineering, physical sciences. 
 
Small Sample Issues 
 WAM’s pipeline is modest, involving 100 young women in each cohort.  For the trialist, 
this invites two themes.  One concerns rhetoric and policy.  The second directs attention to 
technical approaches to handling the matter.  They are interrelated. 
 Small samples of program participants invites the trialist, and WAM’s stakeholders,  to 
denominate the study as exploratory, or as a pilot test. This nomenclature reflects a reality.  Its 
use is important in reducing temptation to over advertise potential results.  More important, it 
lays the groundwork for scaling up or for scaled up trials if indeed the pilot yields promising 
results. 
 Even in small samples,  random assignment guarantees that there will be no systematic 
bias in comparing WAM’s outcomes to a control condition or to other programs.  This is 
fundamental.  Nonetheless, chance outcomes should be taken into account. This is despite the 
fact  artificial thresholds such as p values and statistical power recede in their importance for 
small samples in pilot efforts, and that the magnitude of a discernable difference is important. 
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 Instead of formal tests of hypotheses and the conventional power standards, the trialist 
may employ simpler approaches invented by Fisher, and elaborated and accompanied by 
software by Edgington and Orghena (2007) among others.  Consider the following illustration. 
 Suppose that the outcome variable indicates each woman’s well being on a score with 
range 1-5. Further suppose that the sample is really small, with 5 young ladies being randomly 
assigned to WAM and 5 randomly assigned to a control condition. Such a sample is far too small 
for conventional power analyses or tests of hypotheses unless the expected effect size is huge, 
i.e. the trialist and stakeholders are absurdly optimistic. 
 In simple randomization tests, one ignores the actual assignments and identifies all 
possible assignments of each woman to a group.  In a scenario involving 10 women assigned to 
two groups, there are 252 such assignments.  On then computes the 252 mean differences in the 
scores of the two groups so composed.  At one extreme, for instance, all women in one group 
may have scores of 5 and all women in the other condition have scores of 1, leading to a simple 
difference in average scores of 4. At another extreme, all women in each group  may have the 
same scores, leading to an average difference in outcomes of zero.  Beyond these extremes, there 
is lots of variation. 
 In this hypothetical scenario, 15% of all the average differences between groups may be  
“big” by chance, i.e. an average difference of 1 or more. If the actual observed difference in the 
trial is 1, then one may conclude that the magnitude is big and further that the probability level is 
tolerably small if there is no real WAM effect.  It is not statistically significant under a 5% 
threshold value, but the result is promising. 
  
Concluding Remarks  
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 As readers might surmise, developing fair and transparent estimates of the effects of new 
programs is hard work.  This is the case for WAM as well as others.  The steps need to do the job 
right are numerous.  To some, they are tedious and not fast enough. 
In other scenarios, experiments can indeed be brisker.  The Silicon Valley slogan, “Fail 
often and fast,”  embodies a different perspective on trials for instance.  The context of differs.  
Computer chips are irrelevant to ethical issues.  Web based commercial experiments on 
influencing site user preferences, however,  usually involve fewer steps and less complex 
“programs” than something like WAM.   
The series of questions enunciated above can be reconfigured as checklist items, of 
course.  Taking a checklist approach helps to assure (a) procedural simplicity, (b) action topics 
are covered, (c) the generation of a dependable scientific log on the experiments, and  (d) 
ingredients for interim and final reporting on WAM’s effects. 
Questions other than the three that are posed here can be laid out.  For instance, can 
QWAM be replicated and might  the results of this particular WAM trial be replicated again in 
the same and other contexts?  Further, how might the results of repeated  trials on WAM like 
programs be recorded and submitted to systematic review.  Though organizations such as 
Campbell Collaboration, the Cochrane Collaboration, and others do a good job, they cannot do 
the job well if results of trials are not reported. 
Making incremental progress to assist young pregnant women in low income 
neighborhoods in their learning how to make progress on their own  is important.  The evidence 
on progress is a product of randomized trials.  Absent dependable evidence, the young women 
and we will make little or no progress. 
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